GlassScriptPhysician profile
William L Fan
NPI 1902884000
$5,240.83
in general payments reported to CMS, 2019-2025
26 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $195 · 2021: $410 · 2022: $395 · 2023: $842 · 2024: $1,188 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444 · Education: $76.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,443.94 |
| Education | $76.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $750.93 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $540.02 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $526.78 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $464.92 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $386.76 | 2021-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $323.26 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $271.70 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $252.26 | 2019-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $232.33 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $186.73 | 2019-2024 | Auryxia, Vafseo |
| Novo Nordisk INC | $161.56 | 2023-2025 | Ozempic, Rivfloza, Wegovy |
| Travere Therapeutics, INC. | $160.43 | 2022-2025 | |
| Horizon Therapeutics Plc | $137.66 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $132.91 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $118.35 | 2021-2025 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.51 | 2021-2025 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $106.62 | 2024-2025 | Jardiance |
| Genzyme Corporation | $71.05 | 2019-2024 | |
| Opko Pharmaceuticals, LLC | $60.40 | 2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $55.66 | 2019 | |
| Shire North American Group INC | $54.75 | 2019 | |
| Ardelyx, INC. | $38.74 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.04 | 2024-2025 | Jardiance |
| Amag Pharmaceuticals, INC. | $28.81 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.68 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $15.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.